Summary & Overview
HCPCS G8586: Anti-lipid Treatment Contraindicated
HCPCS Level II code G8586 designates that anti-lipid (lipid-lowering) treatment is contraindicated and is used to document the clinical decision not to initiate or continue such therapy. Nationally, clear documentation of contraindications to lipid-lowering drugs matters for care coordination, quality measurement, and claims accuracy because it differentiates appropriate non-treatment from omissions of care. Key payers with coverage considerations include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
This publication provides a concise national overview of HCPCS Level II code G8586, explaining its clinical context and administrative purpose, and summarizes what readers will learn: how the code is used in outpatient and ambulatory documentation, implications for quality reporting and claims processing, common scenarios that prompt use of the code, and where to find additional payer guidance. It also outlines typical documentation elements associated with a contraindication entry and notes where input data is not available. The content is intended for clinicians, coding professionals, and policy analysts seeking a clear, national-level reference on this specific HCPCS Level II code.
Billing Code Overview
HCPCS Level II code G8586 indicates anti-lipid treatment contraindicated. This code is used to document situations where lipid-lowering therapy is medically contraindicated for a patient and therefore not provided.
-
Service type: Documentation of contraindication to anti-lipid therapy
-
Typical site of service: Ambulatory clinic or outpatient setting where medication decisions and documentation occur
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 72-year-old patient with a history of ischemic heart disease, statin intolerance due to severe myopathy, and active liver disease presents to a cardiology clinic for lipid management. The cardiologist documents that standard anti-lipid therapies (statins, ezetimibe, PCSK9 inhibitors due to immunologic contraindication) are contraindicated for this patient. The clinical workflow includes: initial outpatient evaluation, review of prior adverse reactions and liver function tests, documentation of contraindications in the medical record, discussion of alternative risk-reduction strategies (lifestyle, blood pressure control, antiplatelet therapy), and communication of the contraindication to the patient’s primary care team and pharmacy for medication reconciliation. Billing uses the HCPCS Level II status indicator for reporting that anti-lipid treatment is contraindicated (G8586) when submitting claims to payors such as Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure or other service | Use when an E/M visit for evaluation of contraindication is distinct from other services provided the same day |